Don't miss

Replay


LATEST SHOWS

THE OBSERVERS

The violinist of Venezuela's protests; and France's dying bees

Read more

FOCUS

Famine used as a weapon of war in South Sudan

Read more

THE DEBATE

Let's talk Africa-Asia partnerships (part 2)

Read more

THE DEBATE

Let's talk Africa-Asia partnerships (part 1)

Read more

BUSINESS DAILY

British Airways IT debacle could cost the airline big

Read more

TALKING EUROPE

Security in Europe: Is there more that could or should be done?

Read more

IN THE PAPERS

Is this the end of the Western post-war order?

Read more

THE INTERVIEW

Living with the 'new normal': How govts need to innovate in the fight against terrorism

Read more

IN THE PAPERS

Putin 'gets the tsar treatment' as he meets Macron in Versailles

Read more

SCIENCE

Swiss drugs giant Roche donates anti-viral treatments

Latest update : 2009-05-12

Swiss drugs manufacturer Roche said it is donating 5.65 million treatment courses of its anti-viral drug Tamiflu to help fight the worldwide outbreak of the Influenza A (H1N1) virus.

AFP - Swiss drugs giant Roche said Tuesday it was donating 5.65 million treatment courses of its anti-viral drug Tamiflu to help the World Health Organisation fight the swine flu outbreak.
  
It added in a statement that it would also boost its production capacity for anti-virals, producing another 110 million treatment courses over the next five months.
  
Following that, it would further ramp up capacity to a maximum output of 36 million treatments per month by year-end if required.
  
"The recent outbreak of influenza A(H1N1) shows that such a virus can be totally unexpected and spread rapidly around the globe," said William Burns, CEO of Roche's pharmaceuticals division.
  
The outbreak "emphasises the urgency" of replenishing the stockpiles to prepare for subsequent waves of the virus, he added.
  
Roche said its latest donation would help replenish stockpiles of the UN health agency which have been deployed to deal with the current outbreak.
  
Two million courses of the drug will be held by the WHO, while three million courses will be held by Roche on behalf of the organisation.
  
The remaining 650,000 treatment courses of smaller Tamiflu capsules will form a new pediatric stockpile, said the group.
  
"In view of the uncertain impact of the influenza A(H1N1) virus on the current Southern Hemisphere influenza season, and the subsequent Northern Hemisphere winter season, it will be important for all stakeholders to closely monitor events and continue pandemic preparedness," added Roche.
  
Thirty countries have reported 4,694 laboratory confirmed cases of influenza A(H1N1), including 53 deaths, to the WHO.

Date created : 2009-05-12

COMMENT(S)